Article
Source: Campus Sanofi

InRange Study

Author : Sanofi

Editorial Team

InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo® Insulin Glargine 300U/ml and insulin degludec 100U/mL in people with T1DM.

InRange Clinical Summary

Download this clinical summary about the InRange study and learn more about the study design, the key findings and more.

Download

InRange Study

Professor Richard Bergenstal presents the results of the InRange study. This study is the first randomised controlled trial to compare second generation basal insulin analogues Toujeo^® and insulin degludec 100 U/mL. It compares adults with T1DM, using Time-in-Range (TIR) as the primary endpoint. Watch and learn about the study design and key findings.

Time in Range Guide

View the guide below to find out more about the impact of time in range on your patients.

View guide

See more from science

Toujeo

Toujeo^® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

More about Toujeo

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo^®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo^®.

Access patient materials